EP4167935A1 - Association of natural actives ingredients to fight skin aging - Google Patents
Association of natural actives ingredients to fight skin agingInfo
- Publication number
- EP4167935A1 EP4167935A1 EP20734351.8A EP20734351A EP4167935A1 EP 4167935 A1 EP4167935 A1 EP 4167935A1 EP 20734351 A EP20734351 A EP 20734351A EP 4167935 A1 EP4167935 A1 EP 4167935A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- resveratrol
- composition
- hyaluronic acid
- component
- advantageously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009759 skin aging Effects 0.000 title claims description 11
- 239000004615 ingredient Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 129
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 125
- 229940016667 resveratrol Drugs 0.000 claims abstract description 101
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 94
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 88
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 74
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 71
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 69
- 239000000284 extract Substances 0.000 claims abstract description 52
- 241001644894 Khaya senegalensis Species 0.000 claims abstract description 43
- 239000000178 monomer Substances 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 230000032683 aging Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000036571 hydration Effects 0.000 claims abstract description 12
- 238000006703 hydration reaction Methods 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000014509 gene expression Effects 0.000 claims description 29
- 230000007423 decrease Effects 0.000 claims description 14
- 235000018991 trans-resveratrol Nutrition 0.000 claims description 14
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- -1 a-viniferin Chemical compound 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 7
- 240000006365 Vitis vinifera Species 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 206010011026 Corneal lesion Diseases 0.000 claims description 5
- 208000005577 Gastroenteritis Diseases 0.000 claims description 5
- 208000022873 Ocular disease Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000001079 digestive effect Effects 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 206010023365 keratopathy Diseases 0.000 claims description 5
- 230000017074 necrotic cell death Effects 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 201000004335 respiratory allergy Diseases 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 230000036269 ulceration Effects 0.000 claims description 5
- FQWLMRXWKZGLFI-BQYFGGCBSA-N (+)-trans-epsilon-viniferin Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@H](C=1C=C(O)C=C(O)C=1)[C@@H](C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-BQYFGGCBSA-N 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 claims description 2
- RKFYYCKIHVEWHX-YOBICRQBSA-N (E)-trans-miyabenol C Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@H](C=1C=3[C@H]([C@@H](OC=3C=C(O)C=1)C=1C=CC(O)=CC=1)C=1C=C(O)C=C(O)C=1)[C@@H](C=1C=CC(O)=CC=1)O2 RKFYYCKIHVEWHX-YOBICRQBSA-N 0.000 claims description 2
- YYKOAHPNURGNEH-OAPWRRNMSA-N E-vitisin Natural products Oc1ccc(cc1)[C@@H]2Oc3cc(O)c4[C@H]([C@H]5[C@H]([C@H](c6ccc(O)cc6)c7c(O)cc8O[C@H]([C@H](c9cc(O)cc(O)c9)c8c57)c%10ccc(O)cc%10)c4c3[C@H]2c%11cc(O)cc(O)c%11)c%12ccccc%12 YYKOAHPNURGNEH-OAPWRRNMSA-N 0.000 claims description 2
- OBOUYBKGROJMIK-KOBVKWGYSA-N Miyabenol C Natural products Oc1ccc(C=Cc2cc(O)cc3O[C@H]([C@H](c4cc(O)c5O[C@@H]([C@@H](c6cc(O)cc(O)c6)c5c4)c7ccc(O)cc7)c23)c8ccc(O)cc8)cc1 OBOUYBKGROJMIK-KOBVKWGYSA-N 0.000 claims description 2
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- YQQUILZPDYJDQJ-KGDQSQJYSA-N hopeaphenol Chemical compound C1=CC(O)=CC=C1[C@H](O1)[C@@H]2C3=CC(O)=CC(O)=C3[C@@H](C=3C=CC(O)=CC=3)[C@H]([C@@H]3C=4C=C(O)C=C5O[C@H]([C@@H](C=45)C4=CC(O)=CC(O)=C4[C@H]3C=3C=CC(O)=CC=3)C=3C=CC(O)=CC=3)C3=C2C1=CC(O)=C3 YQQUILZPDYJDQJ-KGDQSQJYSA-N 0.000 claims description 2
- YQQUILZPDYJDQJ-PLGGFYDZSA-N hopeaphenol Natural products Oc1ccc(cc1)[C@@H]2Oc3cc(O)cc4[C@H]([C@@H]5[C@@H](c6ccc(O)cc6)c7c(O)cc(O)cc7[C@@H]8[C@H](Oc9cc(O)cc5c89)c%10ccc(O)cc%10)[C@@H](c%11ccc(O)cc%11)c%12c(O)cc(O)cc%12[C@@H]2c34 YQQUILZPDYJDQJ-PLGGFYDZSA-N 0.000 claims description 2
- DQRZXILSJKXVQV-UHFFFAOYSA-N nepalensinol G Natural products Oc1ccc(cc1)C2OC3=CC(=O)C(=O)C4=C3C2c5cc(O)cc(O)c5C(C4C6C(c7ccc(O)cc7)c8c(O)cc(O)cc8C9C(Oc%10cc(O)cc6c9%10)c%11ccc(O)cc%11)c%12ccc(O)cc%12 DQRZXILSJKXVQV-UHFFFAOYSA-N 0.000 claims description 2
- YNVJOQCPHWKWSO-ZBVBGGFBSA-N pallidol Chemical compound C1=CC(O)=CC=C1[C@@H]1C2=C(O)C=C(O)C=C2[C@@H]2[C@H]1C(C=C(O)C=C1O)=C1[C@H]2C1=CC=C(O)C=C1 YNVJOQCPHWKWSO-ZBVBGGFBSA-N 0.000 claims description 2
- JHXPPGKKFCNRED-UHFFFAOYSA-N pallidol Natural products Oc1ccc(cc1)C1C2C(C(c3c2cc(O)cc3O)c2ccc(O)cc2)c2c1cc(O)cc2O JHXPPGKKFCNRED-UHFFFAOYSA-N 0.000 claims description 2
- PERPNFLGJXUDDW-UHFFFAOYSA-N (E)-3'-beta-D-Glucopyranosyloxy-3,4,5'-trihydroxystilbene Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 PERPNFLGJXUDDW-UHFFFAOYSA-N 0.000 claims 1
- UMGCIIXWEFTPOC-UHFFFAOYSA-N 3,4,3',5'-Tetrahydroxystilbene-3-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(C=CC=2C=C(O)C=C(O)C=2)=CC=C1O UMGCIIXWEFTPOC-UHFFFAOYSA-N 0.000 claims 1
- PERPNFLGJXUDDW-YHDCXSKOSA-N Astringin Natural products OC[C@@H]1O[C@H](Oc2cc(O)cc(C=Cc3ccc(O)c(O)c3)c2)[C@H](O)[C@@H](O)[C@@H]1O PERPNFLGJXUDDW-YHDCXSKOSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003349 gelling agent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000001626 skin fibroblast Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010802 RNA extraction kit Methods 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 101150066399 COL4A1 gene Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101150027313 Has2 gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- GFBCWCDNXDKFRH-UHFFFAOYSA-N 4-(oxan-2-yloxy)phenol Chemical compound C1=CC(O)=CC=C1OC1OCCCC1 GFBCWCDNXDKFRH-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000218665 Gnetaceae Species 0.000 description 1
- 241000534640 Haemodoraceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 description 1
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000234615 Musaceae Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100284369 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) has-1 gene Proteins 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920005903 polyol mixture Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a composition
- a composition comprising as component a) a Khaya Senegalensis extract, as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof, and as component c) hyaluronic acid or a salt thereof, hyaluronic acid derivatives or a salt thereof, or mixtures thereof.
- the present invention also relates to a cosmetic care method for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing, comprising administering an effective amount of the composition of the invention.
- Resveratrol (3, 5, 4'-trihydroxystilbene) is a natural polyphenolic antioxidant of the stilbene family that is found in more than 70 plant species.
- One of the most common botanical sources is the vine; more specifically vine shoot is particularly rich in resveratrol.
- resveratrol is a phytoalexin that protects plants from stress, UV light, microbial infections.
- Resveratrol exists in two isomeric forms, the cis and trans forms, and is presented in monomeric form, or as an oligomer containing several monomeric units.
- resveratrol is a powerful antioxidant and anti-inflammatory agent and has cardiovascular and anti-carcinogenic effects.
- One of its most promising actions is its anti-aging action due to its ability to increase the activity of sirtuins which are longevity genes capable of prolonging the life of cells and organisms (Sinclair D. et al ., Nature, 2003, 425: 191 -196; Steegborn C. et al., PLoS One, 2012, 7 (11 ); Wood JG et al. Nature 430: 686-689).
- WO 99/03816 discloses extraction methods leading to extracts enriched in monomeric and/or oligomeric resveratrol, using groups which protect phenolic functions, more particularly ester groups. These extraction methods allow to confer stability in air and in the light to monomeric and oligomeric resveratrol and render them liposoluble. These protective groups can be then eliminated under determined conditions, which makes it possible to exploit the properties of resveratrol in a controlled manner.
- Resveratrol-Oleyl not only has a protective effect against carbonyl stress (a type of protein modification which occurs during aging) but also has improved skin bioavailability thanks to its stabilization and solubilization by oleic acid.
- Hyaluronic acid is a ubiquitous natural polysaccharide which is formed from repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine, linked together by alternating glycosidic bonds 6-1 ,4 and 6-1 .3. It is widely distributed in various tissues of the body, such as connective, epithelial and nervous tissues. It is therefore suitable for biomedical applications targeting these tissues and is for example used to treat osteoarthritis of the knee. Hyaluronic acid is often used in the form of intra-articular injections, as it would protect the joints by increasing the viscosity of the synovial fluid and making the cartilage more elastic.
- Hyaluronic acid is naturally present in the skin where it plays an important role in hydration and in the biomechanical properties of the skin. Hyaluronic acid, however, decreases in quantity and quality with age, resulting in drying the skin and a decrease in its biomechanical properties, leading thus to wrinkles. Hyaluronic acid is metabolically extremely active. The degradation of hyaluronic acid is first catalyzed by hyaluronidases. Furthermore, polymeric hyaluronic acid can be degraded non- enzymatically by free radicals. The enzymes responsible for the synthesis of hyaluronic acid are the hyaluronan synthases HAS-1 , HAS-2 and HAS-3.
- HAS-2 seems to play a crucial role during development since the deletion of the has-2 gene in mice is lethal at mid-gestation due to numerous cardiovascular malformations (Camenisch TD. Et al., J. Clin. Invest., 2000, 106 (3): 349-60).
- Hyaluronic acid is widely used in dermatology and dermoesthetics to treat the signs of aging. It is injected into the dermis to fill in wrinkles as described in document Kogan, G. et al. (6iotechno. Letter, 2007, 29: 17-25). It has the advantage of being absorbable in the event of bad injection and without side effect, even in treatment over several years. Treatment requires repeated injections at regular intervals, usually 6 to 12 months, in order to maintain a filling action.
- the application FR 3 036 956 relates to compositions comprising resveratrol and hyaluronic acid and in particular to the use of such a composition to stimulate the synthesis of hyaluronic acid.
- These compositions are capable of stimulating the production of hyaluronic acid in order to restore or maintain the biological and biomechanical properties of tissues and having improved properties for the treatment of dysfunctions linked to a deficit in the synthesis of hyaluronic acid, in particular for the treatment and protection of tissues containing hyaluronic acid (skin, cartilage. .), even more particularly for the treatment, slowing down and prevention of skin aging.
- International application WO 2012/116391 discloses a cosmetic or pharmaceutical formulation comprising a crosslinked polymer of hyaluronate and one or more compounds selected from a group comprising in particular resveratrol or one of its derivatives. These compositions stimulate the formation of collagen in the dermis and regulate cell turnover. These compositions can be used against oxidative damage to the dermis and pigmentation problems.
- US 2014/363502 relates to compositions containing resveratrol and their use for modulating the expression of certain genes involved in particular in aging.
- US 2014/363502 discloses a combination of resveratrol and hyaluronic acid. According to this document, the more significant effect of the compositions according to the invention is attributed to better stability of the combined resveratrol compared to resveratrol alone.
- These compositions can be useful in the treatment and prevention of cancers, and age-related diseases, including macular degeneration.
- Khaya senegalensis is a tree also referred to as cailcedrat, belonging to the Meliaceae family and found in several African countries, especially Benin, Cameroon, Senegal, Guinea, Ivory Coast or else Burkina Faso. It is also found in northern Australia and New Caledonia.
- Khaya senegalensis is a plant used for the large-scale construction of dugout canoes in Africa. In addition, its seeds are rich in oleic acid, making therefrom an oil used in West African cuisine. Khaya senegalensis is moreover known as a medicinal plant: the seeds and leaves are used to combat fever and headaches, and the bark is known for its anti-inflammatory properties. Khaya senegalensis bark is used in the treatment of arthritis, lumbago and other joint pains, and also in the treatment of dermatoses. Decoctions of bark of the plant have also been used as disinfectants.
- WO 2017/178751 discloses that an extract of the plant Khaya senegalensis is capable of maintaining and/or increasing the expression of collagen XVIII of the skin and/or the mucous membranes and/or the scalp and/or the skin appendages, in particular at the dermoepidermal junction.
- Such an extract allows thus to increase both the firmness and/or elasticity of the skin and/or the mucous membranes and/or the scalp, and also to decrease the visibility of the pores, that is to say decrease the opening thereof, and/or to make skin smoother and/or to limit and/or reduce perspiration and/or to limit and/or reduce the loss of head hair and/or body hair and/or increase the growth of head hair and/or body hair and/or reduce or limit the production of sebum.
- Patent application WO2012033634 discloses cosmetic anti-aging compositions which may be applied topically, comprising, among other plant extracts, a Khaya senegalensis extract for inhibiting synthesis of metalloproteases 1 (ALMR1 s) and stimulating the synthesis of procollagen I.
- a Khaya senegalensis extract for inhibiting synthesis of metalloproteases 1 (ALMR1 s) and stimulating the synthesis of procollagen I.
- Patent application EP1019016 also discloses a synergistic anti-aging complex intended especially for topical application to the skin and comprising a dehydrated extract of Khaya senegalensis bark, said complex making it possible to combat UV radiation, the inflammatory processes generated by this radiation, and to reduce lipid peroxidation of fibroblasts.
- the inventors have shown a specific effect of the association of a Khaya Senegalensis extract with resveratrol or one of its derivatives and hyaluronic acid or one of its derivatives or a salt thereof, in comparison with each compound alone and with the association of resveratrol or one of its derivatives and hyaluronic acid or one of its salts (without the Khaya Senegalensis extract).
- the present invention thus relates to a composition
- a composition comprising as component a) a Khaya Senegalensis extract, as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof, and as component c) hyaluronic acid or a salt thereof, hyaluronic acid derivatives or a salt thereof, or mixtures thereof.
- the present invention also relates to the use of a composition
- a composition comprising as component a) a Khaya Senegalensis extract, as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof, and as component c) hyaluronic acid or a salt thereof, hyaluronic acid derivatives or a salt thereof, or mixtures thereof, for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing.
- the present invention also relates to a cosmetic care method for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing, comprising topically administering to a subject in need thereof, an effective amount of a composition comprising as component a) a Khaya Senegalensis extract, as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof, and as component c) hyaluronic acid or a salt thereof, hyaluronic acid derivatives or a salt thereof, or mixtures thereof.
- a cosmetic care method for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing
- Figure 1 illustrates the effect of Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) alone (H), Oligo-Resveratrol alone (0), Khaya Senegalensis extract alone (C), an association of Low Molecular Weight Hyaluronic Acid (50 kDa) + Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) + Oligo- Resveratrol (HOR), or an association of Low Molecular Weight Hyaluronic Acid (50 kDa) + Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) + Oligo-Resveratrol + Khaya Senegalensis extract (HORC), on the expression of HAS-2 Genes.
- Sample V corresponds to fibroblasts that were untreated, i.e. that were incubated in the absence of products to be tested.
- Figure 2 illustrates the effect of Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) alone (H), Oligo-Resveratrol alone (O), Khaya Senegalensis extract alone (C), an association of Low Molecular Weight Hyaluronic Acid (50 kDa) + Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) + Oligo- Resveratrol (HOR), or an association of Low Molecular Weight Hyaluronic Acid (50 kDa) + Very Low Molecular Weight Hyaluronic Acid (0,5-10 KDa) + Oligo-Resveratrol + Khaya Senegalensis extract (HORC), on the expression of COL4A1 Genes.
- Sample V corresponds to fibroblasts that were untreated, i.e. that were incubated in the absence of products to be tested.
- alkyl group refers to a linear or branched saturated hydrocarbon chain.
- alkylene group refers to a linear or branched, divalent, saturated hydrocarbon chain.
- aryl group refers to an aromatic hydrocarbon group comprising preferably 6 to 10 carbon atoms and comprising one or more, notably 1 or 2, fused rings, such as, for example, a phenyl or naphtyl group.
- arylene group refers to an divalent aromatic hydrocarbon group comprising preferably 6 to 10 carbon atoms and comprising one or more, notably 1 or 2, fused rings, such as, for example, a phenyl or naphtyl group.
- alkylaryl group refers to an aryl group as defined above bound to the molecule via an alkyl group as defined above.
- arylalkyl group refers to an alkyl group as defined above bound to the molecule via an aryl group as defined above.
- heterocycle refers to a saturated, unsaturated or aromatic hydrocarbon monocycle or polycycle (comprising fused, bridged or spiro rings), such as a bicycle, in which one or more, advantageously 1 to 4, and more advantageously 1 or 2, carbon atoms have each been replaced with a heteroatom selected from nitrogen, oxygen and sulphur atoms.
- the heterocycle comprises 5 to 15, notably 5 to 10 atoms in the ring(s).
- Each ring of the heterocycle has advantageously 5 or 6 members.
- “increasing the expression of genes” is intended to mean an increase in the level of genes expression, preferably of at least 1.5-fold, more preferably still of at least 2-fold, relative to the gene expression detected in the absence of treatment.
- the invention relates to a composition
- a composition comprising as component a) a Khaya Senegalensis extract, as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof, and as component c) hyaluronic acid or one of its salts, hyaluronic acid derivatives or one of its salts, or mixtures thereof.
- the Khaya Senegalensis extract may be any extract of all or part of the plant Khaya Senegalensis.
- the Khaya Senegalensis extract is an extract of the root, bark, flower, seed, seedling, aerial parts, in particular the stem of the branches and/or the leaf, and mixtures thereof.
- the Khaya Senegalensis extract according to the invention is a bark extract.
- the Khaya Senegalensis extract may be obtained by plant extraction methods known by the one skilled in the art, in particular by solid/liquid extraction, for example maceration.
- the Khaya Senegalensis extract is obtained by solid/liquid extraction, for example maceration, of at least one part of the plant in a solvent such as water, alcohol, polyol, glycol and mixtures thereof.
- the Khaya Senegalensis extract is obtained by solid/liquid extraction of at least one part of the plant, in particular the bark, in a solvent selected from the group consisting of water, alcohol, polyol, glycol or mixtures thereof, more advantageously in a solvent selected for the group consisting of water/alcohol, water/glycol or water/polyol mixtures in proportion of between 0/100 and 100/0 (v/v) of water/alcohol, polyol or glycol, preferably between 20/80 and 100/0 (v/v), more preferably between (60/40 and 100/0).
- the extract of Khaya Senegalensis is obtained by aqueous solid/liquid extraction.
- aqueous solid/liquid extraction is intended to mean any solid/liquid extraction as defined above with an aqueous solvent comprising at least 60% by weight, advantageously at least 70% by weight, in particular at least 80% by weight, more particularly at least 90% by weight, particularly at least 95% by weight, of water relative to the total weight of the aqueous solvent, even more advantageously 100 % by weight of water.
- the extract of Khaya Senegalensis is obtained by solid/liquid extraction of an amount of 10% to 20% by weight of bark relative to the total weight of bark and of solvent, in an aqueous solvent, in particular in water as sole solvent.
- the extract of Khaya Senegalensis is obtained by solid /extraction as disclosed in the international application WO 2017/178751 , in particular from page 12, line 31 to page 15, line 22 and in example 1.
- the extract of Khaya Senegalensis used in the invention is advantageously enriched in oligo- proanthocyanidins (OPC).
- OPC oligo- proanthocyanidins
- the extract of Khaya Senegalensis used in the invention comprises advantageously at least 3%, more advantageously between 3 % to 7 % by weight of OPC, in relation with the total weight of the extract.
- the extract of Khaya Senegalensis used in the invention is also advantageously enriched in polyphenols.
- the extract of Khaya Senegalensis used in the invention comprises advantageously at least 10 %, more advantageously between 10 % to 14 % by weight of polyphenols, expressed in Gallic acid equivalent.
- the composition also comprises as component b) resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters, or mixtures thereof.
- component b) can be a compound selected from the group of resveratrol, resveratrol monomers, resveratrol oligomers, resveratrol esters; a mixture of two or more of said compounds; or an extract enriched in said compounds, preferably a vine extract.
- resveratrol (3, 5, 4'-trihydroxystilbene) can exist in two isomeric forms, the c/ ' s and trans forms (see formula (I) and (II) respectively):
- component b) comprises resveratrol
- it is in the form of trans- resveratrol (formula (II)).
- resveratrol monomers are resveratrol derivatives, in particular trans- resveratrol derivatives, comprising one monomer unit, such as E-piceid, E-astringin, E-pterostilbene or E-piceatannol.
- resveratrol oligomers are resveratrol derivatives comprising two or more resveratrol monomer units, in particular 2, 3 or 4 resveratrol monomer units, such as e-viniferin, d-viniferin, pallidol, a-viniferin, miyabenol C, E-vitisin B, or hopeaphenol.
- resveratrol esters are monomers or oligomers of resveratrol, wherein the monomers comprises at least one ester group of formula (III), and the oligomers are formed of two or more monomer units, in particular 2, 3 or 4 monomer units, comprising at least one ester group of formula (III), the monomer units being joined by carbon-carbon bonds, or ether, and/or the oligomers are formed of monomers crosslinked by at least one group of formula (IV):
- A represents an alkyl group of at least two carbon atoms, linear or branched, saturated or unsaturated; an aryl group; arylalkyl group; or an alkylaryl group, and
- R represents an alkylene group from 0 to 10 carbon atoms, saturated or unsaturated; an arylene group having 1 to 3 rings; a heterocyclic group, and the diastereoisomers of these units.
- resveratrol esters according to the invention are as disclosed in the international application WO 99/03816, in particular from page 2 line 18, to page 5 line 2.
- the method of preparation of the resveratrol esters is also disclosed in WO 99/03816.
- resveratrol esters are resveratrol esters of fatty acid. More advantageously, resveratrol esters are of one of the following fatty acids: butyric acid C4:0; valeric acid C5:0; hexanoic acid C6:0; sorbic acid C6:2(n-2); lauric acid C12:0; palmitic acid C16:0; stearic acid C18:0; oleic acid C18: 1 (n-9); linoleic acid C18:2(n-6); linolenic acid C18:3(n-6); a-linolenic acid C18:3(n-3); arachidonic acid C20:4(n-3), eicosapentaenoic acid C20:5(n-3); and docosahexanoic acid C22:6(n-3).
- A is advantageously a (C4-C2s)-alkyl group, more advantageously a (C4-C22)- alkyl group, more advantageously a Ci 6 -alkyl group (i.e. C16-fatty acid).
- resveratrol, resveratrol monomers, resveratrol oligomers, and/or resveratrol esters can be chemically synthesized or obtained from various plant sources selected from the following group: Vitaceae, Umbelliferae, Myrtaceae, Dipterocarpaceae, Cyperaceae, Gnetaceae, Legumes, Grasses, Seraceae, Haemodoraceae, Musaceae, Polygonaceae, Pinaceae, Cupressaceae, Cesalpiniaceae, Poaceae, and Solanaceae.
- the resveratrol, resveratrol monomers, resveratrol oligomers, and/or resveratrol esters are obtained by extracting grape vines using water and/or an organic solvent, by techniques known to the one skilled in the art, such as techniques disclosed in WO 99/03816.
- the resveratrol, resveratrol monomers, resveratrol oligomers, and/or resveratrol esters can also be obtained by use of genetically modified microorganisms from animal tissue or by bioproduction from plants, in particular from suspensions of vine cells ( Study of the synthesis of resveratrol and its derivatives by
- the component b) is in the form of an extract rich in resveratrol from grape vines, in particular in the form of an extract rich in resveratrol, resveratrol monomers, resveratrol oligomers, and/or resveratrol esters.
- the component b) is an extract of grape vines enriched in trans- resveratrol and/or resveratrol oligomers, preferably enriched in trans- resveratrol and resveratrol oligomers such as e- viniferin, d-viniferin, and a-viniferin. More advantageously, the component b) is an extract of grape vines comprising trans- resveratrol and e-viniferin.
- the component b) is an extract of grape vines comprising frans-resveratrol in a content of between 10 and 30 % by weight, and e-viniferin in a content of between 10 and 20 % by weight, in relation to the total weight of the extract.
- the component b) is a mixture of resveratrol, resveratrol monomers, resveratrol oligomers, and/or resveratrol esters.
- the component b) is a mixture comprising at least resveratrol, in particular frans- resveratrol and/or resveratrol oligomers, in particular e-viniferin, d-viniferin, and a-viniferin.
- the component b) is a mixture comprising mainly frans-resveratrol and/or e- viniferine. More advantageously, the component b) is a mixture comprising frans-resveratrol in a content of between 10 and 30 % by weight, and e-viniferin in a content of between 10 and 20 % by weight, in relation to the total weight of the extract.
- composition of the invention also comprises as component c) hyaluronic acid or a salt thereof, hyaluronic acid derivatives or a salt thereof, or mixtures thereof.
- hyaluronic acid refers to a linear polymer consisting of the repetition of the disaccharides of D-glucuronic acid and N-acetyl-D- glucosamine, linked together via alternating 6-1 ,4 and 6-1 ,3 glycosidic bonds ([-6(1 ,4)-GlcUA-6(1 ,3)- GlcNAc-]n).
- Hyaluronic acid is a naturally occurring, not sulphated glycosaminoglycan (GAG).
- GAG sulphated glycosaminoglycan
- Hyaluronic acid is widely available commercially or may be prepared or extracted by any technique known to those skilled in the art. This polymer may be natural or synthetic.
- Hyaluronic acid derivatives means its counterparts, analogs, derivatives, complexes, esters, fragments and subunits.
- Hyaluronic acid exists naturally in the form of unsaturated disaccharides (Acta Vet Scand. 2015 Mar 4; 57(1 ): 12) and can also be chemically modified so as to improve its absorption characteristics, such as for example by modifications of the hydroxyl groups by an ether bond to obtain a cysteine conjugate-hyaluronic acid (Chem Commun (Camb). 2015 51 (47): 9662-5) or the formation of an ethyl ether of l-cysteine (C) via an amide bond (J Pharm Sci. 2015 Apr 21. doi: 10.1002/jps.24456).
- hyaluronic acid salt or ‘hyaluronic acid derivatives salt” is understood to mean the sodium, potassium, magnesium, aluminium, or ammonium salts, in particular sodium or potassium salts.
- the average molecular weight of the hyaluronic acid or derivatives thereof used varies according to the administration mode.
- the average molecular weight of hyaluronic acid or derivatives thereof is advantageously at most 100 kDa, more advantageously between 0.5 kDa and 100 kDa, more advantageously between 0.5 kDa and 50 kDa, and even more advantageously between 5 kDa and 50 kDa.
- high molecular weight hyaluronic acid or derivatives thereof is advantageously used, such as more than 1 Million Dalton, in particular between 1.2 and 2.1 Millions Da.
- component c) is hyaluronic acid and/or hydrolysed hyaluronic acid of average molecular weight of at most 100 kDa, more advantageously between 0.5 kDa and 100 kDa, even more advantageously between 0.5 kDa and 50 kDa, and even more advantageously between 5 kDa and 50 kDa.
- the amounts of components a), b) and c) in the composition will be determined by those skilled in the art in the light of their general knowledge.
- the composition is advantageously formulated so that component b) is administered at a dose of between 10 mg per day and 5 g per day.
- the cosmetic or dermatological composition is advantageously formulated so that component a) represents from 0.05 to 5% by weight of the composition, component b) represents from 0.01 to 1% by weight of the composition and component c) represents 0.01 to 0.4% by weight of the composition.
- the composition is advantageously formulated in the form of an aqueous solution comprising advantageously between 1 pg/ml and 100 mg/ml of component a), between 1 pg/ml and 100 mg/ml of component b) and between 1 pg/ml and 100 mg/ml of component c).
- These doses can be administered once or several times a day.
- the composition of the invention comprises between 0.02 % and 5 %, more advantageously between 0.5 and 2%, by weight of component a), in relation to the total weight of the composition.
- the composition of the invention comprises between 0.01 % and 1 %, more advantageously between 0.3 and 1%, by weight of component b), in relation to the total weight of the composition.
- the composition of the invention comprises between 0.01 % and 0.4 %, more advantageously between 0.01 and 0.2 %, by weight of component c), in relation to the total weight of the composition.
- the composition of the invention comprises between 0.5 % and 2 % of component a), between 0.3 % and 1 % of component b), and between 0.01 % and 0.2 % of component c).
- the composition of the invention comprises an extract of Khaya Senegalensis bark as component a), a mixture comprising at least trans- resveratrol or resveratrol oligomers as component b), and hyaluronic acid or hydrolysed hyaluronic acid of average molecular weight of at most 100 kDa as component c).
- the composition of the invention comprises an aqueous extract of Khaya Senegalensis bark as component a), a mixture comprising mainly trans- resveratrol and e-viniferin, as component b), and hyaluronic acid or hydrolysed hyaluronic acid of average molecular weight of at most 100 kDa as component c).
- the composition of the invention comprises an aqueous extract of Khaya Senegalensis bark as component a), a grape vine extract comprising mainly trans- resveratrol or resveratrol oligomers, in particular e-viniferin, as component b), and hyaluronic acid or hydrolysed hyaluronic acid of average molecular weight of between 5 and 100 kDa as component c).
- the composition of the invention further comprises other active principles, in particular active principles with anti-aging properties such as b-carotene, vitamin E or vitamin C, Oligo-ProanthoCyanidines (OPC), retinol, cis-retinoic acid, trans-retinoic acid, retinyl palmitate salicylic acid, niacinamide, nicotinic acid, phytic acid, N-acetyl L-cysteine, azelaic acid, lipoic acid, lactic acid, glycolic acid, panthenol, arbutin, deoxyarbutin, kojic acid, allantoin, cholesterol, C10- C30 cholesterol/lanosterol esters, tocopherol, tocopheryl acetate, and mixtures thereof.
- active principles with anti-aging properties such as b-carotene, vitamin E or vitamin C, Oligo-ProanthoCyanidines (OPC), retinol, cis-retinoic
- composition of the invention may be formulated in the form of various preparations for oral, parenteral or topical administration, preferably for topical administration.
- the composition of the invention is a cosmetic composition, a food composition, a pharmaceutical composition, a dermatological composition or a veterinary composition.
- the modes of administration, dosing schedules and optimal galenic forms of the components and composition of the invention may be determined according to the criteria generally taken into account in the establishment of a pharmaceutical, dermatological, cosmetic, food or veterinary treatment suitable for a patient or an animal, such as for example the age or the body weight of the patient or animal, the severity of the general condition of the patient or animal, tolerance to the treatment, noted side effects, skin type.
- the composition and/or components of the invention may further include at least one acceptable carrier, in particular a pharmaceutically acceptable, a dermatologically acceptable carrier, a cosmetically acceptable carrier, a food acceptable carrier, or a veterinary acceptable carrier.
- composition according to the present invention may furthermore comprise at least one known excipient commonly used in those fields, chosen from oils, waxes, emollients, solvents, pigments, dyes, polymers, surfactants, rheological agents, perfumes, electrolytes, adjusters of pH, fillers, chemical or mineral filters, chelating agents, odor absorbers, thermal spring water, antioxidants, gelling agents, for example hydrophilic or lipophilic gelling agents, moisturizing agents, thickeners, and preservatives.
- excipient commonly used in those fields, chosen from oils, waxes, emollients, solvents, pigments, dyes, polymers, surfactants, rheological agents, perfumes, electrolytes, adjusters of pH, fillers, chemical or mineral filters, chelating agents, odor absorbers, thermal spring water, antioxidants, gelling agents, for example hydrophilic or lipophilic gelling agents, moisturizing agents, thickeners, and preservatives.
- the composition is a cosmetic composition for topical use comprising an effective amount of components a), b) and c), and further comprising at least one cosmetically acceptable excipient chosen from oils, waxes, emollients, solvents, pigments, dyes, polymers, surfactants, rheological agents, perfumes, electrolytes, adjusters of pH, fillers, chemical or mineral filters, chelating agents, odor absorbers, thermal spring water, antioxidants, gelling agents, for example hydrophilic or lipophilic gelling agents, moisturizing agents, thickeners, and preservatives.
- the amounts of these various excipients are those traditionally used in cosmetics.
- the amount of each excipient may vary from 0.01 % to 20 % by weight, in relation to the total weight of the cosmetic composition.
- the cosmetic composition is a skin care or makeup product and is for example in the form of a gel, a cream, a pomade, a lotion, an emulsion, a milk, an oil, an ointment, a foam, a serum, a hydrogel, a mask, an aerosol, a stick, for example for a lipstick, an aqueous or water-alcoholic or glycolic solution, a powder, or a patch.
- the composition is a pharmaceutical, dermatological or veterinary composition, for topical, oral or parenteral administration. It can also be in the form of a food composition, in particular a food supplement.
- a composition comprises an effective amount of components a), b) and c), and further comprises a physiologically acceptable carrier.
- the pharmaceutical, dermatological, veterinary or food composition comprises an effective amount of components a), b) and c), and a suitable excipient chosen from oils, waxes, emollients, solvents, pigments, dyes, polymers, surfactants, rheological agents, perfumes, electrolytes, adjusters of pH, fillers, chemical or mineral filters, chelating agents, odor absorbers, thermal spring water, antioxidants, gelling agents, for example hydrophilic or lipophilic gelling agents, moisturizing agents, thickeners, and preservatives.
- a suitable excipient chosen from oils, waxes, emollients, solvents, pigments, dyes, polymers, surfactants, rheological agents, perfumes, electrolytes, adjusters of pH, fillers, chemical or mineral filters, chelating agents, odor absorbers, thermal spring water, antioxidants, gelling agents, for example hydrophilic or lipophilic gelling agents, moisturizing agents, thickeners, and preservatives.
- the composition for oral administration is advantageously in the form of tablets, capsules, powders, granules, lyophilisates, solutes, suspensions, syrups, drinks, pastes, chewing gum or candy.
- the composition for parenteral administration is advantageously in the form of an aqueous solution or of a lyophilized powder.
- the pharmaceutical, dermatological, cosmetic, veterinary or food compositions according to the invention are for use for treating and/or preventing disorders associated to a reduction in hyaluronic acid, a decrease of the expression of HAS2 genes, and/or a decrease in the expression of COL4A1 genes.
- the cosmetic composition of the invention is for use for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing; advantageously for maintaining or restoring hydration of the skin and the biomechanical properties of the skin and/or to prevent or delay the appearance of signs of aging of the skin, in particular the appearance of wrinkles and the loss of firmness of the skin or to slow down the effects; in particular for preventing, slowing down or correcting skin aging, in particular for firming the skin, and/or promoting the attenuation or resorption of wrinkles.
- the cosmetic composition of the invention is for use for increasing the expression of HAS2 genes or COL4A1 genes.
- the present invention also relates to a cosmetic care method for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing, comprising topically administering an effective amount of a composition according to the invention to a subject in need thereof.
- the cosmetic care method is for maintaining or restoring hydration of the skin and the biomechanical properties of the skin and/or to prevent or delay the appearance of signs of aging of the skin, in particular the appearance of wrinkles and the loss of firmness of the skin or to slow down the effects.
- the cosmetic care method is for preventing, slowing down or correcting skin aging, in particular for firming the skin, and/or promoting the attenuation or resorption of wrinkles.
- the present invention also relates to the cosmetic use of the cosmetic composition of the invention for maintaining or restoring hydration of the skin and/or for preventing or delaying skin ageing, advantageously for maintaining or restoring hydration of the skin and the biomechanical properties of the skin and/or to prevent or delay the appearance of signs of aging of the skin, in particular the appearance of wrinkles and the loss of firmness of the skin or to slow down the effects, in particular for preventing, slowing down or correcting skin aging, more particularly for firming the skin, and/or promoting the attenuation or resorption of wrinkles.
- compositions according to the invention are more particularly for use for treating and/or preventing osteoarthritis and skin aging.
- the pharmaceutical, dermatological, veterinary or food compositions may also be for use for preventing and/or treating pathologies affecting the mucous membranes of the respiratory tract, such as asthma, respiratory allergies, respiratory distress syndrome, or digestive disorders, in particular gastroenteritis, ischemic necrosis and ulcerations of the intestinal mucosa.
- the pharmaceutical, dermatological, veterinary or food compositions according to the invention can be for use for treating ocular disorders, in particular dryness of corneal lesions and keratopathies.
- the present invention thus also relates to the composition of the invention for use as a drug, in particular for preventing and/or treating osteoarthritis; skin aging; pathologies affecting the mucous membranes of the respiratory tract, such as asthma, respiratory allergies, respiratory distress syndrome; digestive disorders, such as gastroenteritis, ischemic necrosis and ulcerations of the intestinal mucosa; or ocular disorders, such as dryness of corneal lesions and keratopathies.
- the present invention also relates to the composition of the invention for use for preventing and/or treating disorders associated to a reduction in hyaluronic acid, a decrease of the expression of HAS2 genes, and/or a decrease in the expression of COL4A1 genes.
- the present invention thus also relates to a method for preventing and/or treating osteoarthritis; skin aging; pathologies affecting the mucous membranes of the respiratory tract, such as asthma, respiratory allergies, respiratory distress syndrome; digestive disorders, such as gastroenteritis, ischemic necrosis and ulcerations of the intestinal mucosa; or ocular disorders, such as dryness of corneal lesions and keratopathies; comprising administering to a subject in need thereof, an effective amount of the composition of the invention.
- the present invention thus also relates to a method for preventing and/or treating disorders associated to a reduction in hyaluronic acid, a decrease of the expression of HAS2 genes, and/or a decrease in the expression of COL4A1 genes, comprising administering to a subject in need thereof, an effective amount of the composition of the invention.
- the present invention also relates to the use of the composition of the invention for the manufacture of a drug for preventing and/or treating osteoarthritis; skin aging; pathologies affecting the mucous membranes of the respiratory tract, such as asthma, respiratory allergies, respiratory distress syndrome; digestive disorders, such as gastroenteritis, ischemic necrosis and ulcerations of the intestinal mucosa; or ocular disorders, such as dryness of corneal lesions and keratopathies.
- the present invention also relates to the use of the composition of the invention for the manufacture of a drug for preventing and/or treating disorders associated to a reduction in hyaluronic acid, a decrease of the expression of HAS2 genes, and/or a decrease in the expression of COL4A1 genes.
- Example 1 Effect of the composition of the invention on the expression of the has2 genes and COL4A1 genes in human skin fibroblasts - Comparison with each compound individually.
- GOAL To determine the activity of Oligo-Resveratrol (OR, R), Low Molecular Weight Hyaluronic Acid (50 kDa) (HHA, H), Very Low Molecular Weight-Hyaluronic Acid (0.5-10 kDa) (OHA, 0), Khaya Senegalensis extract (CL, C) and their combination on the expression of the has2 genes and COL4A1 genes in human skin fibroblasts.
- RNA extraction kit (Zymo Research; Cat #: ZR1057) iScript kit (Biorad; Cat #: 170-8891 )
- the vegan collagen booster (Khaya Senegalensis extract), a hydrophilic liquid (1 g; from Caudalie, stored at room temperature)
- Very Low Molecular Weight HA (0.5-10 kDa), a hydrophilic powder.
- Hyaluronic Acid 50 kDa
- the solubility is 100 g/L (500 mg; from Caudalie, stored at 4°C)
- Oligo-resveratrol (Batch BX1191834), a hydrophobic powder.
- RNA extraction is carried out using the Omega RNA extraction kit. 1 mg of RNA is used and transcribed into complementary DNA using the Bio-Rad iScriptTM cDNA synthesis kit followed by quantification by quantitative real-time PCR.
- PCR reactions were carried out using the FastStartTM DNA Master SYBR Green I real-time PCR kit (Roche Molecular Biochemicals). Each PCR was carried out in a final volume of 20 pi containing 10 m ⁇ of SYBR Green mix 2X (Fast start DNA master SYBR green + Taq DNA polymerase), 2 m ⁇ of the primer mixture and 8 m ⁇ of cDNA solution.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2020/067140 WO2021254637A1 (en) | 2020-06-19 | 2020-06-19 | Association of natural actives ingredients to fight skin aging |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4167935A1 true EP4167935A1 (en) | 2023-04-26 |
Family
ID=71130960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20734351.8A Pending EP4167935A1 (en) | 2020-06-19 | 2020-06-19 | Association of natural actives ingredients to fight skin aging |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4167935A1 (en) |
WO (1) | WO2021254637A1 (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758984B1 (en) | 1997-02-03 | 1999-04-16 | Serobiologiques Lab Sa | ACTIVE SYNERGISTIC COMPLEX AND COSMETIC AND / OR PHARMACEUTICAL PRODUCT COMPRISING THIS COMPLEX |
FR2766176B1 (en) | 1997-07-15 | 1999-10-29 | Caudalie | COMPOSITIONS BASED ON RESVERATROL DERIVATIVES |
US20090169585A1 (en) | 2003-10-23 | 2009-07-02 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity |
FR2923717B1 (en) | 2007-11-15 | 2015-01-16 | Caudalie | COMPOSITIONS OF STILBENIC POLYPHENOLIC DERIVATIVES AND THEIR APPLICATIONS FOR COMBATING PATHOLOGIES AND ENHANCING LIVING ORGANISMS |
WO2012033634A2 (en) | 2010-09-09 | 2012-03-15 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
US9931289B2 (en) | 2011-02-09 | 2018-04-03 | Forward Scout Enterprises Pty Ltd | Cosmetic or pharmaceutical formulation |
US20150005391A1 (en) | 2013-06-26 | 2015-01-01 | COLE Research & Design, Inc. | Method of reducing scarring |
US10470987B2 (en) * | 2015-06-05 | 2019-11-12 | Tomcat International Limited | Process for stimulating hyaluronic acid synthesis |
FR3036956B1 (en) | 2015-06-05 | 2019-12-20 | President And Fellows Of Harvard College | METHOD OF STIMULATING THE SYNTHESIS OF HYALURONIC ACID |
FR3049859B1 (en) | 2016-04-12 | 2023-11-03 | Basf Beauty Care Solutions France Sas | COSMETIC USE OF KHAYA SENEGALENSIS EXTRACT |
-
2020
- 2020-06-19 WO PCT/EP2020/067140 patent/WO2021254637A1/en unknown
- 2020-06-19 EP EP20734351.8A patent/EP4167935A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021254637A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102008925B1 (en) | Retinal cyclodextrin acetals and hemiacetals for clarifying skin complexion | |
US20060233738A1 (en) | Composition for promoting production of type 1 collagen and/or elastin | |
JP6670166B2 (en) | Cosmetics | |
KR20130083788A (en) | Composition for improving skin wrinkle and enhancing elasticity | |
FR3018191A1 (en) | COSMETIC USES OF SWERTIAMARIN | |
EP2170331B1 (en) | Synergistic combination of proanthocyanidins, gamma-tocotrienol and niacin | |
CN112368367A (en) | Composition comprising alpha-lipoic acid or alpha-lipoate, vitamin C derivatives and hyaluronic acid and use thereof | |
EP3302409B1 (en) | Process and composition for stimulating hyaluronic acid synthesis | |
JP2015027998A (en) | Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator | |
JP6173362B2 (en) | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, TRPV4 activator, intracellular Ca concentration increase promoter and sebum production promoter | |
FR3036956A1 (en) | METHOD FOR STIMULATING THE SYNTHESIS OF HYALURONIC ACID | |
JP6861134B2 (en) | Hyaluronic acid production promoter and hyaluronic acid production promoter food | |
JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
EP4167935A1 (en) | Association of natural actives ingredients to fight skin aging | |
JP2012051837A (en) | Glutathione production promoter | |
JP5300233B2 (en) | Skin cosmetics | |
CN113813202A (en) | Combination of natural active ingredients for combating skin ageing | |
JP5171752B2 (en) | Topical skin preparation | |
JP2003342179A (en) | Agent for aging prevention | |
JP2015221791A (en) | External or internal preparation for skin containing extract of ipomoea aquatica cultivated under irradiation with light having specific wavelength band | |
WO2013132873A1 (en) | Promoter for expression of hyaluronic acid synthase gene | |
JP2015093848A (en) | Skin cosmetic and hair cosmetic | |
JP6595195B2 (en) | Skin external preparation or internal preparation containing an extract of chicory cultivated by irradiation with light having a specific wavelength range | |
KR101720712B1 (en) | Composition for improving skin comprising levistilide A | |
KR20200073523A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Lithospermum Erythrorhizon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230112 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE Owner name: CAUDALIE GROUP LIMITED |